

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6239654

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.	10/16/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BIOHAVEN THERAPEUTICS LTD.
<b>Street Address:</b>	215 CHURCH STREET
<b>City:</b>	NEW HAVEN
<b>State/Country:</b>	CONNECTICUT
<b>Postal Code:</b>	06510
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16449948
<b>Application Number:</b>	16689150
<b>Patent Number:</b>	10485791
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	patents@biohavenpharma.com
<b>Correspondent Name:</b>	BIOHAVEN PHARMACEUTICALS, INC.
<b>Address Line 1:</b>	215 CHURCH STREET
<b>Address Line 4:</b>	NEW HAVEN, CONNECTICUT 06510
<b>ATTORNEY DOCKET NUMBER:</b>	20007-US
<b>NAME OF SUBMITTER:</b>	DMITRY ZUEV
<b>SIGNATURE:</b>	/Dmitry Zuev/
<b>DATE SIGNED:</b>	08/07/2020
<b>Total Attachments: 2</b>	
source=20007_CONF_ASG#page1.tif	
source=20007_CONF_ASG#page2.tif	

### CONFIRMATORY ASSIGNMENT

This confirmatory assignment is by and between Biohaven Pharmaceutical Holding Company Ltd., a British Virgin Islands company with principal offices located at 215 Church Street New Haven, CT 06510, United States ("Assignor") and Biohaven Therapeutics Ltd., a British Virgin Islands company with principal offices located at 215 Church Street New Haven, CT 06510, United States ("Assignee").

Assignor hereby confirms that effective July 1, 2019 ("Effective Date"),

pursuant to contractual obligations heretofore assumed by Assignor and for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Assignor sold, assigned, transferred and set over to Assignee, its entire right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to Assignor by local laws or by treaty, including the International Convention for the Protection of Industrial Property, in and for all countries of the world, including the United States and its territories and possessions, in and to the inventions and subject matter described in the United States provisional patent application:

Application No. 62/127684, filed, March 3, 2015

entitled:


### PRODRUGS OF RILUZOLE AND THEIR USE

including said United States provisional patent application as of its filing date and any application claiming priority from said provisional application, filed in any country, including without limitation United States patent application no. 15/549154, filed August 5, 2017, and any patents which may be issued and/or granted thereon, and all divisions, continuations, reissues, reexamination certificates and extensions thereof in all countries, said interest being the entire ownership of said inventions and subject matter and all of said applications, patents (including reissue patents), extensions and reexamination certificates to be held and enjoyed by said Assignee, its successors, assigns and legal representatives to the full end of the terms of which said patents (including reissue patents), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by Assignor if this sale, assignment and transfer had not been made; and

Assignor agrees, as of the Effective Date, to communicate to said Assignee or its representatives any facts known to Assignor respecting said inventions and subject matter, to testify in any legal proceedings, to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of all applications, including divisional, continuation and reissue applications, extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said inventions and subject matter and all of said applications, patents (including reissue patents, extensions and reexamination certificates in said Assignee), and in general to do everything possible to aid said Assignee, its successors, assigns and legal representatives to obtain and enforce proper protection for said inventions and subject matter in all countries to the extent deemed necessary or desirable by said Assignee, its successors, assigns or legal representatives.

Signed this 16<sup>th</sup> day of October, 2019.

**BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.**

By: 

Name: Jim Engelhart

Title: CFO

**BIOHAVEN THERAPEUTICS LTD.**

By: 

Name: Vlad Coric, M.D.

Title: CEO

**WITNESS:**

By: 

Name: Warren K. Volles